GTI-2501. Lorus Therapeutics.
Lorus Therapeutics (formerly GeneSense Technologies) is developing GTI-2501, directed against the R1 component of ribonucleotide reductase, for the potential treatment of cancer [348928]. In November 2000, the company filed an IND with the FDA in preparation to begin a phase I trial in the US in the first quarter of 2001 [389975], [396537], [397960]. In March 2001, the FDA approved the IND application [402350], and in June 2001, a phase I, dose-escalating trial in patients with lymphomas or solid tumors which have not responded to standard therapy commenced in the US [412225]. The company expected the phase I trial of GTI-2501 to be completed within 12 to 15 months [420582]. In November 1999, the company reported that in preclinical trials, GTI-2501 was an effective anticancer agent when tested in standard mouse models bearing a variety of different human cancer lines including tumor cells derived from lung, breast, colon, kidney, ovary pancreas and skin cancers [348928]. Lorus received a patent from the US PTO in January 2000, covering the design and use of unique anitisense anticancer drugs, including GTI-2501 and GTI-2040 [353538]. In June 2000, the USPTO allowed a patent to specifically protect GTI-2501 [370810].
Tu
G C
GC
Department of Pathology, Cell Biology and Anatomy, Thomas Jefferson University, Philadelphia, PA 19107, USA. Guang-Chou.Tu@mail.tju.edu
Tu
X
X
D000818:Animals; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D017321:Clinical Trials, Phase I as Topic; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy*; D009369:Neoplasms / Q000188:drug therapy*; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000633:toxicity; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D009841:Oligonucleotides; D016376:Oligonucleotides, Antisense; C464618:GTI2501